We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... E+P continues to ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...

In GALAXIES, there was a “clinically meaningful” reduction at every dose of the combination tested compared to monotherapy with Jemperli or MSD’s PD-1 inhibitor Keytruda (pembrolizumab ...

Atezolizumab (as Tecentriq Hybreza) can also be given as an injection under the skin (subcutaneously) over several minutes, typically once every 3 weeks. Pembrolizumab (Keytruda) and nivolumab (Opdivo ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...